Catalyst Pharmaceuticals

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Catalyst Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 7 completed top decile by trial count

Catalyst Pharmaceuticals: 10 sponsored US clinical trials, 1 recruiting.

Catalyst Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 5 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cocaine Dependence, with 2 trials.

Top-decile sponsor footprint

Catalyst Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

NCT06564974
TERMINATED Phase 3

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

NCT03579966
COMPLETED Phase 3

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

NCT03304054
COMPLETED Phase 3

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

NCT02970162
COMPLETED Phase 3

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

NCT02562066
COMPLETED Phase 1

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

NCT01493596
COMPLETED Phase 3

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

NCT01377922
COMPLETED Phase 2

Vigabatrin for the Treatment of Cocaine Dependency

NCT01281202
TERMINATED Phase 2

Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

NCT00730522
COMPLETED Phase 2

Vigabatrin for Treatment of Cocaine Dependence

NCT00611130

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 5

Therapeutic Areas

Cocaine Dependence 2
Lambert-eaton Myasthenic Syndrome 2
Cocaine Addiction 1
Myasthenic Syndromes, Congenital 1
Duchenne Muscular Dystrophy 1

What is open in the Catalyst Pharmaceuticals pipeline

1 recruiting of 10 indexed (10% open); 7 completed (70%).

Phase mix: 5 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Cocaine Dependence (2 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Catalyst Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Catalyst Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Catalyst PharmaceuticalsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Catalyst Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Catalyst Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Catalyst Pharmaceuticals page

10 registered trials is a research-attention snapshot, not an endorsement of Catalyst Pharmaceuticals or any single study.

  • 1 of Catalyst Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cocaine Dependence is the condition Catalyst Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cocaine Dependence trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Catalyst Pharmaceuticals pipeline card: 10 registered trials from official public datasets.Report a data error.